论文部分内容阅读
目的：为提高卵巢癌抗独特型抗体的免疫原性，构建表达６Ｂ１１ｓｃＦｖ／ｈＧＭＣＳＦ融合蛋白质，并对其活性进行测定。方法：用ＤＮＡ重组技术，将以前构建的６Ｂ１１ｓｃＦｖＬｉｎｋｅｒｈＧＭＣＳＦ融合基因克隆至ｐＥＴ１６（ａ＋）表达载体，表达可溶蛋白质。用ＥＬＩＳＡ分析技术和细胞增殖试验测定融合蛋白质的抗体和细胞因子活性。结果：融合蛋白质实现可溶表达，能与ＣＯＣ１６６９单抗和小鼠抗人ＧＭＣＳＦ单抗特异结合，并能刺激ＧＭＣＳＦ依赖株增殖。结论：融合蛋白质保留了２种蛋白质的活性，为进一步研究其功能和临床应用提供基础
OBJECTIVE: To improve the immunogenicity of anti-idiotypic antibodies against ovarian cancer, a fusion protein expressing 6B11scFv / hGM-CSF was constructed and its activity was determined. METHODS: The previously constructed 6B11scFv-Linker-hGM-CSF fusion gene was cloned into pET16 (a +) expression vector using DNA recombinant technology to express soluble proteins. Antibody and cytokine activity of the fusion protein was determined by ELISA assay and cell proliferation assay. Results: The fusion protein was expressed soluble, with COC166 9 monoclonal antibody and mouse anti-GM-CSF monoclonal antibody specific binding, and can stimulate the proliferation of GM CSF dependent strains. Conclusion: The fusion protein retains the activity of two proteins, providing a basis for further study of its function and clinical application